Cabaletta Bio, Inc.
NASDAQ:CABA
3.71 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cabaletta Bio, Inc. |
Symbool | CABA |
Munteenheid | USD |
Prijs | 3.71 |
Beurswaarde | 181,228,677 |
Dividendpercentage | 0% |
52-weken bereik | 3.471 - 26.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Steven A. Nichtberger M.D. |
Website | https://www.cabalettabio.com |
An error occurred while fetching data.
Over Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)